C4 Therapeutics (CCCC) Competitors

C4 Therapeutics (NASDAQ:CCCC) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

Do insiders & institutionals believe in CCCC or FULC?

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is CCCC or FULC more profitable?

Fulcrum Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. Fulcrum Therapeutics' return on equity of -7.31% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-313.35%	-42.45%	-27.55%
Fulcrum Therapeutics	N/A	-7.31%	-6.74%

Which has more volatility & risk, CCCC or FULC?

C4 Therapeutics has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500.

Does the MarketBeat Community favor CCCC or FULC?

Fulcrum Therapeutics received 75 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.82% of users gave Fulcrum Therapeutics an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote.

Company	Underperform	Outperform
C4 Therapeutics	Outperform Votes 27 38.57%	Underperform Votes 43 61.43%
Fulcrum Therapeutics	Outperform Votes 102 61.82%	Underperform Votes 63 38.18%

Do analysts recommend CCCC or FULC?

C4 Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 640.74%. Fulcrum Therapeutics has a consensus target price of $6.29, indicating a potential downside of 7.29%. Given C4 Therapeutics' higher probable upside, research analysts clearly believe C4 Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fulcrum Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Which has preferable valuation and earnings, CCCC or FULC?

Fulcrum Therapeutics has higher revenue and earnings than C4 Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$39.78M	2.89	-$132.49M	-$1.47	-1.10
Fulcrum Therapeutics	$80M	4.57	-$97.33M	-$0.07	-96.86

Does the media refer more to CCCC or FULC?

In the previous week, Fulcrum Therapeutics had 10 more articles in the media than C4 Therapeutics. MarketBeat recorded 11 mentions for Fulcrum Therapeutics and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.89 beat Fulcrum Therapeutics' score of 1.13 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
C4 Therapeutics	Very Positive
Fulcrum Therapeutics	Positive

Summary

Fulcrum Therapeutics beats C4 Therapeutics on 13 of the 18 factors compared between the two stocks.